The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the identification and characterization in one patient of T-cell receptors (TCRs) recognizing mutated p53 p.R175H, which is shared among a subset of patients with cancer. Tumor-infiltrating lymphocytes were screened for recognition of mutated neoantigens in a patient with metastatic colorectal cancer. HLA-A*0201–restricted recognition of mutated p53 p.R175H was identified, and the minimal peptide epitope was HMTEVVRHC. Reactive T cells were isolated by tetramer sorting, and three TCRs were identified. These TCRs mediated recognition of commercially available ovarian cancer, uterine carcinoma, and myeloma cell lines, as well as an NIH patient–derived esophageal adenocarcinoma line that endogenously expressed p53 p.R175H and HLA-A*0201. They also mediated recognition of p53 p.R175H+ colon, breast, and leukemia cell lines after transduction with a retrovirus encoding HLA-A*0201. This work demonstrates that common shared mutated epitopes such as those found in p53 can elicit immunogenic responses and that the application of ACT may be extended to patients with any cancer histology that expresses both HLA-A*0201 and the p53 p.R175H mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Self-citationTherapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Research works printed but not linked: 11
- Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 · DOI · Paper page
- Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 · DOI · Paper page
- Stevanovic, 2017, Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer, Science, 356, 200, 10.1126/science.aak9510 · DOI · Paper page
- Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
- Zehir, 2017, Erratum: mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, 23, 1004, 10.1038/nm0817-1004c · DOI
- Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
- Favero, 2015, Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data, Ann Oncol, 26, 64, 10.1093/annonc/mdu479 · DOI · Paper page
- Dudley, 2003, Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, Journal of Immunotherapy, 26, 332, 10.1097/00002371-200307000-00005 · DOI · Paper page
- Lu, 2014, Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions, Clin Cancer Res, 20, 3401, 10.1158/1078-0432.CCR-14-0433 · DOI · Paper page
- Lu, 2018, An efficient single-cell RNA-Seq approach to identify neoantigen-specific T cell receptors, Mol Ther, 26, 379, 10.1016/j.ymthe.2017.10.018 · DOI
- Gonzalez-Galarza, 2015, Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations, Nucleic Acids Res, 43, D784, 10.1093/nar/gku1166 · DOI · Paper page
Cited by
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023) · Science Advances · doi:10.1126/sciadv.adf3700 · Cited by 429
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Metadata
- Authors
- Lo, W., Parkhurst, M., Robbins, P. F., Tran, E., Lu, Y.-C., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D., Malekzadeh, P., Shelton, T. E., Prickett, T., Ray, S., Kivitz, S., Paria, B. C., Kriley, I., Schrump, D. S., & Rosenberg, S. A.
- Venue
- Cancer Immunology Research
- Published
- 2019-04-01
- Volume
- 7
- Issue
- 4
- Pages
- 534-543
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2913440788
- Cited by
- 158
- References
- 5
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0686
- The paper
- Lo, W., Parkhurst, M., Robbins, P. F., Tran, E., Lu, Y.-C., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D., Malekzadeh, P., Shelton, T. E., Prickett, T., Ray, S., Kivitz, S., Paria, B. C., Kriley, I., Schrump, D. S., & Rosenberg, S. A. (2019). Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0686
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
